Drugs / Onalespib
Onalespib
also known as
AT13387 · A13387 · AT-13387 LACTATE · ATI-13387A · ATI-13387AU · ATI-13387X · CPD 35 · ONALESPIB (AT13387) · +2 more
Trials 13
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2013-07-22 | Astex Pharmaceuticals, Inc. | Results Astex Pharmaceuticals Announces First Data Showing Early Combination Treatment of HSP90 Inhibitor AT13387 With Targeted Agents Delays Emergence of Resistance in Preclinical Models astx.com ↗
today announced data demonstrating for the first time that early treatment with AT13387, a second generation, fully synthetic HSP90 inhibitor, in combination with targeted therapy delays the emergence of resistance. |
| 2011-09-27 | Astex Pharmaceuticals, Inc. | Results Evidence of AT13387 Activity in Gastrointestinal Stromal Tumor Models Presented at ECCO astx.com ↗
The HSP90 inhibitor was as active, or more active, than 17 -AAG, a first generation HSP90 inhibitor, in all the cell lines tested. |
| 2010-11-11 | Astex Pharmaceuticals, Inc. | Results Encouraging Data from Phase I Studies of Astex’s Anti-Cancer Drugs AT7519, AT9283 and AT13387 to be Presented at EORTC-NCI-AACR Annual Meeting astx.com ↗
There was a dose dependent effect of AT13387 on HSP70 induction resulting in a significant increase at doses above 60mg/kg. |
| 2010-07-29 | Astex Pharmaceuticals, Inc. | Results Astex scientists describe novel HSP90 inhibitors in two key publications in Journal of Medicinal Chemistry astx.com ↗
The companion paper describes how the lead compound was optimised into the clinical candidate, AT13387, a potentially best -in-class HSP90 inhibitor which is entering into Phase II clinical trials for the treatment of a variety of cancers. |
| 2010-06-02 | Astex Pharmaceuticals, Inc. | Results Encouraging Interim Data From A Phase I Study Of Astex’s HSP90 Inhibitor AT13387 To Be Presented At ASCO astx.com ↗
Interim clinical data, to be presented by Dr Shapiro, indicate that AT13387 is well tolerated, with no dose limiting toxicities observed at doses up to 120mg/m2/day. |
| 2009-11-09 | Astex Pharmaceuticals, Inc. | Results Astex to disclose the structure of its HSP90 inhibitor, AT13387, at the AACR-NCI-EORTC Annual Meeting 2009 astx.com ↗
These new data illustrate that AT13387 has a significantly longer duration of action compared to natural product based or other synthetic small molecule HSP90 inhibitors in the field, a property that could allow for less frequent dosing of AT13387. |
| 2008-02-06 | Astex Pharmaceuticals, Inc. | Regulatory Astex Receives IND Approval for its Small Molecule HSP90 Inhibitor AT13387; Astex Announces Extension of Drug Discovery Alliance astx.com ↗
Astex Therapeutics announced today that it has received approval of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for AT13387, a selective small molecule inhibitor of Heat Shock Protein 90 (Hsp90) to treat cancer. |
All press releases naming this drug 10 releases
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Onalespib | “Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387)” PMID 26082332 ↗ Jun 20158“Onalespib (AT13387) is a potent non-ansamycin HSP90 inhibitor.” PMID 27156227 ↗ May 2016 |
| Known as | A13387 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1214827 ↗ |
| Known as | AT-13387 LACTATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1214827 ↗ |
| Known as | AT13387 | “Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387)” PMID 26082332 ↗ Jun 20155“Onalespib (AT13387) is a potent non-ansamycin HSP90 inhibitor.” PMID 27156227 ↗ May 2016 |
| Known as | ATI-13387A | ChEMBL registry synonym — accepted as the source's own label CHEMBL1214827 ↗ |
| Known as | ATI-13387AU | ChEMBL registry synonym — accepted as the source's own label CHEMBL1214827 ↗ |
| Known as | ATI-13387X | ChEMBL registry synonym — accepted as the source's own label CHEMBL1214827 ↗ |
| Known as | CPD 35 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1214827 ↗ |
| Known as | ONALESPIB (AT13387) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1214827 ↗ |
| Known as | Onalespib l-lactate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1214827 ↗ |
| Known as | Onalespib Lactate | “Drug: Onalespib Lactate” NCT02535338 ↗ |
| Action | Inhibit | “Onalespib (AT13387) is a potent non-ansamycin HSP90 inhibitor.” PMID 27156227 ↗ May 2016 |
| Modality | Small molecule | — CHEMBL1214827 ↗ |
| Route | Intravenous | “one hour intravenous (IV) infusions” NCT00878423 ↗ |